NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
With reference to company announcements no. 2/2017 dated 6 November 2017 and no. 5/2017 dated 16 November 2017, Orphazyme A/S ("Orphazyme") today announces the completion of its Initial Public Offering (the "IPO" or "Offering") and admission to trading and official listing on Nasdaq Copenhagen A/S ("Nasdaq Copenhagen").
The Offering has today proceeded to completion and the admission to trading and official listing on Nasdaq Copenhagen today becomes unconditional. The offer shares allocated to investors in the form of temporary purchase certificates, as described in company announcement no. 5/2017 dated 16 November 2017, as well as the shares allocated to, among others, certain members of the Board of Directors, Executive Management and certain key employees in connection with exercise of their respective pre-IPO warrants, as described in the offering circular published by Orphazyme on 6 November 2017, have been settled.
As a result, Orphazyme's share capital has been increased by 8,338,092 new shares of a nominal value of DKK 1 each, which has been registered with the Danish Business Authority.
Following the share capital increase, the total nominal share capital of Orphazyme is DKK 19,928,184, divided into 19,928,184 shares each with a nominal value of DKK 1. Each share carries one vote at Orphazyme's general meetings. Updated Articles of Association can be found at www.orphazyme.com.
The offer shares are delivered in the form of temporary purchase certificates under the temporary ISIN (DK0060911055). On 22 November 2017, the temporary purchase certificates will automatically be exchanged in VP SECURITIES A/S for a corresponding number of shares in Orphazyme under the permanent ISIN (DK0060910917). In connection with the automatic exchange, the temporary purchase certificates will cease to exist.
The last day of trading of the temporary purchase certificates will be 20 November 2017, and the first day of trading of Orphazyme's shares will be 21 November 2017. Consequently, after the trading has closed on Nasdaq Copenhagen on 20 November 2017, all future trading in Orphazyme's shares on Nasdaq Copenhagen will continue and settle under the permanent ISIN (DK0060910917) and under the symbol "ORPHA".
Carnegie and Danske Bank are acting as Joint Global Coordinators and Joint Bookrunners, and Oddo BHF SCA is acting as Co-Lead Manager for the IPO.
For additional information, please contact
Anders Hinsby, CEO +45 31 44 31 39